Trial Profile
PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Ebvaciclib (Primary) ; Fulvestrant; Hormone modulators; Letrozole
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 02 Mar 2023 Planned End Date changed from 5 Apr 2023 to 28 Nov 2024.
- 04 Oct 2022 Planned End Date changed from 23 Jan 2024 to 5 Apr 2023.
- 04 Oct 2022 Planned primary completion date changed from 20 Feb 2023 to 5 Apr 2023.